CD163 and neoplasm: Compared with pre-treatment or with post-treatment samples from the Ipilimumab group, the combination enhanced the intratumoral endothelial activation, resulting in increased trafficking of CD8+ T cells and CD163+ dendritic macrophages across the tumor vasculature.